OHE Lunchtime Seminar with Professor Aslam H. Anis, University of British Columbia, Vancouver’s Centre for Health Evaluation and Outcome Sciences and the CIHR Canadian HIV Trials Network

The impact of price-cap regulations on entry and exit by generic pharmaceutical firms in Canada

Monday 23rd February 2015, 12:00-2:00pm.
Sir Alexander Fleming room, 7th Floor, Southside, 105 Victoria Street, London, SW1E 6QT

A buffet lunch will be available from 12:00 noon. The seminar will start promptly at 12.30 pm and finish promptly at 2.00 pm

Pharmaceutical markets Canada are unique in that generic drugs are subject to various 'price-cap' regulations set by provincial governments. Canada's largest pharmaceutical market, the province of Ontario, has been a leader in setting generic price-cap regulations in relation to the price of the brand-name drug, and has since the early 1990s adopted progressively lower price-caps. In his upcoming lecture, Dr. Aslam Anis will report the results of studies describing the impact of the latest wave of price-caps instituted in Canadian provinces since 2010, including Ontario's regulation requiring generic drugs to be sold at 25% of the brand-name product's price, the lowest price-cap in Canada’s history. Two separate studies were conducted, the first to assess the impact of the price-cap regulations on market exit by generic suppliers in the province of Ontario, the second to assess the impact on market entry by generic drug suppliers in 9 Canadian provinces with various price-cap levels. Provincial drug formulary listings (2003-2012) as well as Canada’s National Prescription Drug Utilization Information System Database (2004-2013) were used to track the status of generic drugs, and separate statistical models were developed to compare the incidence of market exit (Poisson regression) and market entry (logistic regression) across different policy periods while controlling for market features.

Dr. Aslam Anis is a renowned Canadian health economist who has conducted numerous studies of the impact of various types of regulatory instruments and policies on the pharmaceutical marketplace in Canada. This includes price-cap regulations on generic drug prices and market dynamics in Canada. Dr. Anis is a Professor of Health Economics in the School of Population and Public Health, University of British Columbia, is the Director of Vancouver’s Centre for Health Evaluation and Outcome Sciences and National Director of the CIHR Canadian HIV Trials Network.

If you would like to attend this seminar please reply to Kerry Sheppard (ksheppard@ohe.org). If you are unable to attend but think that a colleague might like to, please pass on this letter to them.

Yours faithfully

Adrian Towse
Director